Phase I study of oral S-1 and concurrent radiotherapy in patients with head and neck cancer

This study investigated the maximum tolerated dose (MTD) of S-1 with concurrent radiotherapy in patients with head and neck cancer, based on the frequency of dose-limiting toxicities (DLT). S-1 was administered orally at escalating doses from 40 mg/m(2) b.i.d. on the days of delivering radiotherapy,...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakata, Kensei, Sakata, Koh-ichi, Someya, Masanori, Miura, Katsutoshi, Hayashi, Junichi, Hori, Masakazu, Takagi, Masaru, Himi, Tetsuo, Kondo, Atsushi, Hareyama, Masato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709662/
https://www.ncbi.nlm.nih.gov/pubmed/23292146
http://dx.doi.org/10.1093/jrr/rrs133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709662/
https://www.ncbi.nlm.nih.gov/pubmed/23292146
http://dx.doi.org/10.1093/jrr/rrs133

Ejemplares similares